Lamivudin/Zidovudin Accord

Lamivudine and Zidovudine, the active ingredients in Lamivudin/Zidovudin Accord, are nucleoside reverse transcriptase inhibitors presented as a fixed‑dose oral tablet for oral use. They are employed in the management of HIV‑1 infection in adults, children, and pregnant women, and are part of standard combination regimens recommended by the WHO.

GNH USA supplies Lamivudin/Zidovudin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for antiretroviral therapies across global markets.

Lamivudin/Zidovudin Accord is used in antiretroviral therapy targeting HIV‑1 infection.

- HIV‑1 infection (adults): reduces plasma viral load and helps restore CD4+ T‑cell counts in treatment‑naïve adults. - HIV‑1 infection (children): provides age‑appropriate dosing to control viral replication in pediatric patients. - HIV‑1 infection (pregnant women): used to decrease maternal viral load and reduce the risk of mother‑to‑child transmission.

Lamivudin/Zidovudin Accord may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Fatigue: general tiredness. - Diarrhea: loose stools. - Anemia: mild reduction in hemoglobin. - Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects: - Severe neutropenia: marked decrease in neutrophil count. - Lactic acidosis: rare metabolic complication. - Hepatotoxicity: significant liver injury. - Pancreatitis: inflammation of the pancreas. - Stevens‑Johnson syndrome: severe skin reaction.

When prescribing Lamivudin/Zidovudin Accord, clinicians should consider several precautionary measures to ensure safe use.

- Baseline laboratory tests: obtain CBC, liver function, and renal function before initiation. - Monitoring: perform regular CBC and liver enzyme assessments during therapy. - Pregnancy: weigh benefits against potential risks; use only if clearly needed. - Drug resistance: avoid in patients with documented resistance to lamivudine or zidovudine. - Concomitant hepatotoxic drugs: use with caution when combined with other agents that affect liver. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Lamivudin/Zidovudin Accord can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis and mitochondrial toxicity. - Stavudine: heightened potential for peripheral neuropathy and lactic acidosis. - Efavirenz: may reduce plasma concentrations of zidovudine.

Moderate Interactions (Monitor Closely): - Ribavirin: additive hematologic toxicity, monitor blood counts. - Mycophenolate mofetil: possible enhanced bone marrow suppression. - Non‑nucleoside reverse transcriptase inhibitors (e.g., nevirapine): may affect drug levels, require monitoring.